Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis on Track for Record High Close — Data Talk Provided by Dow Jones Jun 30, 2025, 8:04:00 AM Novartis AG Sponsored ADR (NVS) is currently at $120.93, up $0.92 or 0.77% ...

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) ...

This study has the purpose to answer how the Lipoprotein (a) (Lp (a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between ...

Seeking to develop novel medicines for cardiovascular disease, Novartis and ProFound Therapeutics have signed a four-year strategic collaboration. The agreement will allow the partners to combine ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence ...

Biogen has emerged as a front-runner at the Cannes Lions, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia.